Scarica l'app Stockscreener
5.215
10.72%
0.505
Dopo l'orario di chiusura:
5.07
-0.145
-2.78%
Precedente Chiudi:
$4.71
Aprire:
$4.6
Volume 24 ore:
50,024
Relative Volume:
2.35
Capitalizzazione di mercato:
$41.11M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.67%
1M Prestazione:
+25.97%
6M Prestazione:
+9.10%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.545
$5.215
Intervallo di 1 settimana:
$4.545
$5.50
Portata 52W:
$3.4962
$50.82
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Nome
Radiopharm Theranostics Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta RADX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
5.215 | 36.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Borsa (RADX) Ultime notizie
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% – Here’s Why - Defense World
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and COMPASS Pathways (CMPS) - The Globe and Mail
Radiopharm signs supply agreement with Cyclotek for prostate cancer drug - Investing.com
Radiopharm wins FDA fast track for cancer imaging agent By Investing.com - Investing.com South Africa
Radiopharm wins FDA fast track for cancer imaging agent - Investing.com
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
radiopharm theranostics begins patient dosing in new trial - Investing.com
radiopharm theranostics begins patient dosing in new trial By Investing.com - Investing.com India
radiopharm theranostics shares preclinical data on new cancer therapy By Investing.com - Investing.com South Africa
radiopharm theranostics shares preclinical data on new cancer therapy - Investing.com
Radiopharm secures lutetium-177 supply agreement By Investing.com - Investing.com South Africa
Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM - TipRanks
Radiopharm secures lutetium-177 supply agreement - Investing.com
Radiopharm advances RAD204 trial with expedited phase By Investing.com - Investing.com India
Radiopharm advances RAD204 trial with expedited phase - Investing.com
RADX: Initiating Coverage – Adding a Radioisotope to Precision Oncology - Zacks Small Cap Research
ThinkEquity initiates Radiopharm stock with Buy, $15 target By Investing.com - Investing.com India
ThinkEquity initiates Radiopharm stock with Buy, $15 target - Investing.com
Radiopharm advances brain cancer diagnosis with new trial By Investing.com - Investing.com South Africa
Radiopharm advances brain cancer diagnosis with new trial - Investing.com
Radiopharm Theranostics says new data confirms positive tumour uptake - Biotech Dispatch
Radiopharm Theranostics Engages in Key Healthcare Conferences - TipRanks
B.Riley sets $15 target on Radiopharm Theranostics stock - Investing.com India
Radiopharm Theranostics Announces Director’s Interest Change and Securities Cessation - TipRanks
Radiopharm joins B Riley Radiopharma Conference - Investing.com
Radiopharm reveals positive brain metastases trial data - Investing.com India
Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
Radiopharm Theranostics Ltd Adr Azioni (RADX) Dati Finanziari
Non sono disponibili dati finanziari per Radiopharm Theranostics Ltd Adr (RADX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):